Thereapeutic device for migraine treatment granted FDA clearance

"Theranica, a prescribed digital therapeutics (PDT) company, has announced its Nerivio therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older The use of the device in the treatment of adolescents is supported by a study recently published in Headache.
10% of all school age children and up to 28% of teens between the ages of 15-19 live with migraine. 37% of children find that their schoolwork suffers during a headache and it can negatively affect a teen’s social life as well.
Dr. Jennifer McVige, a physician in paediatric neurology, adult and paediatric headache and neuroimaging at the DENT Neurologic Institute, said: “Having this drug-free migraine therapy available for the adolescent migraine community could positively impact patient compliance. Teens do not always want to take pills, and some may be unable to do so due to various contraindications ..." Lire la suite